BDNF plasma levels variations in major depressed patients receiving duloxetine

Michele Fornaro, Andrea Escelsior, Giulio Rocchi, Benedetta Conio, Paola Magioncalda, Valentina Marozzi, Andrea Presta, Bruno Sterlini, Paola Contini, Mario Amore, Pantaleo Fornaro, Matteo Martino

研究成果: 雜誌貢獻文章同行評審

18 引文 斯高帕斯(Scopus)


It has been frequently reported that brain-derived neurotrophic factor (BDNF) plays an important role in the pathophysiology of major depressive disorder (MDD). Objective of the study was to investigate BDNF levels variations in MDD patients during antidepressant treatment with duloxetine. 30 MDD patients and 32 healthy controls were assessed using Hamilton Depression Scale (HAM-D) and monitored for BDNF plasma levels at baseline, week 6 and week 12 of duloxetine treatment (60 mg/day) and at baseline, respectively. According to early clinical response to duloxetine (defined at week 6 by reduction >50 % of baseline HAM-D score), MDD patients were distinguished in early responders (ER) and early non-responders (ENR), who reached clinical response at week 12. Laboratory analysis showed significant lower baseline BDNF levels among patients compared to controls. During duloxetine treatment, in ENR BDNF levels increased, reaching values not significantly different compared to controls, while in ER BDNF levels remained nearly unchanged. Lower baseline BDNF levels observed in patients possibly confirm an impairment of the NEI stress-adaptation system and neuroplasticity in depression, while BDNF increase and normalization observed only in ENR might suggest differential neurobiological backgrounds in ER vs. ENR within the depressive syndrome.

頁(從 - 到)729-734
期刊Neurological Sciences
出版狀態已發佈 - 5月 1 2015

ASJC Scopus subject areas

  • 皮膚科
  • 神經病學(臨床)
  • 精神病學和心理健康


深入研究「BDNF plasma levels variations in major depressed patients receiving duloxetine」主題。共同形成了獨特的指紋。